Developing the Active Ingredient

Sudhakar Singh, Managing Editor

With the increasing incidence of chronic diseases and growing importance of generics, the Active Pharmaceutical Ingredient (API) market is on a path of continuous growth. New technology adoption such as AI-based tools for drug discovery is further fueling the progress of the market. In this special issue, we have focused on this segment. The cover story of this issue features Kimia Biosciences which has carved a niche for itself in devising demand-driven APIs, intermediaries and formulations. In order to provide newer, more innovative, but reasonably priced products across all therapeutic categories, Kimia Biosciences strives to establish itself as a premier destination of the pharmaceutical industry for APIs in India and beyond. Kimia Biosciences is engaged in manufacturing bulk drugs addressing various high potential therapeutic segments. The company has envisaged high growth plans through infrastructure creation and CMS. Kimia has set aside a sizable amount of investment for over the next two years in order to establish itself as a key player in the Indian and international markets. Also featuring in the issue is Divi’s Laboratories which is one of the leading names in the Indian API market and it has one of the world’s largest API manufacturing facilities. Operating out of Hyderabad, it has been able to develop into one of the most notable names in not just the Indian API market but across the globe and today, the company offers world class products to more than 95 countries.

Keeping tabs on this market, we have shortlisted the top 10 companies that have exhibited an unrelenting pursuit of excellence. By proving their dedication to fulfilling customer expectations and contributing to the market’s evolution through their innovative disposition, these companies are blazing a trail for others to follow and setting an example for them.

We look forward to receiving your feedback and suggestions.

© 2024 India Pharma Outlook. All Rights Reserved.